PMID- 32116716
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in 
      Advanced Cancer: A Systematic Review and Meta-Analysis.
PG  - 40
LID - 10.3389/fphar.2020.00040 [doi]
LID - 40
AB  - BACKGROUND: Combination therapy with immune checkpoint inhibitors (ICIs) has been 
      applied in the clinic to achieve synergistic effects and to improve clinical 
      efficacy. Compared with monotherapy, combination therapy has promising efficacy 
      against various advanced cancers. To further verify the effectiveness of 
      combination therapy, we conducted a meta-analysis of the efficacy and safety of 
      nivolumab (NIVO) and NIVO plus ipilimumab (IPI) in advanced cancer. METHODS: 
      Electronic databases (PubMed, EMbase, and The Cochrane Library) were 
      systematically searched for applicable studies published in English between 
      January 1990 and June 2019. Relevant outcomes included objective response rate 
      (ORR), disease control rate (DCR), median progression-free survival (mPFS), 
      median overall survival (mOS), and grade 3-4 adverse events (AEs). RESULTS: A 
      total of 1,297 patients from six studies were included. Compared with NIVO alone, 
      NIVO + IPI was more efficacious for advanced tumors. Pooled outcome values were: 
      ORR, 1.73 (95% CI: 1.34-2.23); DCR, 1.80 (95% CI: 1.21-2.69); mPFS, 0.22 (95% CI: 
      0.03-0.41); mOS, 0.03 (95% CI: -0.20-0.26); and grade 3-4 AEs, 3.64 (95% CI: 
      2.86-4.62). CONCLUSION: NIVO + IPI is more effective than NIVO alone for the 
      treatment of advanced cancer and can significantly improve ORR and DCR and 
      prolong mPFS. Due to the limited quality and quantity of the included studies, 
      more high-quality studies are needed to validate the above conclusions.
CI  - Copyright (c) 2020 Yang, Jin, Pang, Huang, Wang, Zhang, Tuo, Wu, Wang and Zhu.
FAU - Yang, Yi
AU  - Yang Y
AD  - Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, China.
AD  - Department of Clinical Medicine, Gansu University of Traditional Chinese 
      Medicine, Lanzhou, China.
FAU - Jin, Gang
AU  - Jin G
AD  - Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, China.
FAU - Pang, Yao
AU  - Pang Y
AD  - Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, China.
FAU - Huang, Yijie
AU  - Huang Y
AD  - School of Health Preservation and Rehabilitation, Chengdu University of 
      Traditional Chinese Medicine, Chengdu, China.
FAU - Wang, Wenhao
AU  - Wang W
AD  - Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, China.
FAU - Zhang, Hongyi
AU  - Zhang H
AD  - Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, China.
FAU - Tuo, Guangxin
AU  - Tuo G
AD  - Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, China.
AD  - Department of Clinical Medicine, Gansu University of Traditional Chinese 
      Medicine, Lanzhou, China.
FAU - Wu, Peng
AU  - Wu P
AD  - Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, China.
AD  - Department of Clinical Medicine, Gansu University of Traditional Chinese 
      Medicine, Lanzhou, China.
FAU - Wang, Zequan
AU  - Wang Z
AD  - Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, China.
FAU - Zhu, Zijiang
AU  - Zhu Z
AD  - Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20200214
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7033417
OTO - NOTNLM
OT  - advanced cancer
OT  - combination immunotherapy
OT  - efficacy
OT  - ipilimumab
OT  - nivolumab
OT  - safety
EDAT- 2020/03/03 06:00
MHDA- 2020/03/03 06:01
PMCR- 2020/02/14
CRDT- 2020/03/03 06:00
PHST- 2019/09/06 00:00 [received]
PHST- 2020/01/14 00:00 [accepted]
PHST- 2020/03/03 06:00 [entrez]
PHST- 2020/03/03 06:00 [pubmed]
PHST- 2020/03/03 06:01 [medline]
PHST- 2020/02/14 00:00 [pmc-release]
AID - 10.3389/fphar.2020.00040 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Feb 14;11:40. doi: 10.3389/fphar.2020.00040. eCollection 
      2020.